Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1897 • 2019 ACR/ARP Annual Meeting
Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story
Martín Valdez-López¹, Jonathan Campos-Guzmán ¹, Ana Barrera-Vargas ², Samuel Govea-Peláez ¹, Diana Gómez-Martín ¹, Jorge Alcocer-Varela ¹, Eduardo Aguirre-Aguilar ¹, Diana Padilla-Ortíz ³ and Javier Merayo-Chalico ¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Universidad De La Sabana, Bogotá, Cundinamarca, Colombia
Background/Purpose: Although SLE is uncommon in men, the disease is usually more severe and requires more aggressive immunosuppression in male patients. There are multiple studies…
Abstract Number: 2116 • 2019 ACR/ARP Annual Meeting
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Lisa Lindsay¹, Ching-Yi Chuo ², Nicholas Jones ², Joshua Galanter ², Anna McGregor ² and Katie Tuckwell ², ¹Genentech Inc, SOUTH SAN FRANCISCO, CA, ²Genentech Inc, SOUTH SAN FRANCISCO
Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact…
Abstract Number: 2527 • 2019 ACR/ARP Annual Meeting
Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Emil Åkerström ¹, Christopher Sjöwall ², Azita Sohrabian ³, Andreas Jönsen ⁴, Alvaro Gomez ¹, Martina Frodlund ², Agneta Zickert ¹, Anders Bengtsson ⁴, Johan Rönnelid ³ and Iva Gunnarsson ¹, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁴Lund University, Lund, Sweden
Background/Purpose: The anti-BAFF monoclonal belimumab is approved for the treatment of systemic lupus erythematosus (SLE) since 2011. Effects of belimumab on anti-double stranded (ds)DNA levels,…
Abstract Number: 2562 • 2019 ACR/ARP Annual Meeting
Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018
Anselm Mak¹, Mike W.L.- Cheung ¹, Wai Yee Joanna Leong ², Bhushan Dharmadhikari ³, Nien Yee Kow ³, Michelle Petri ⁴, Susan Manzi ⁵, Ann Clarke ⁶, Cynthia Aranow ⁷, Laurent Arnaud ⁸, Anca Askanase ⁹, Sang-Cheol Bae ¹⁰, Sasha Bernatsky ¹¹, Ian Bruce ¹², Jill Buyon ¹³, W. Winn Chatham ¹⁴, Nathalie Costedoat-Chalumeau ¹⁵, MA Dooley ¹⁶, Paul Fortin ¹⁷, Ellen M Ginzler ¹⁸, Dafna Gladman ¹⁹, Caroline Gordon ²⁰, John G Hanly ²¹, Murat Inanc ²², David A Isenberg ²³, Soren Jacobsen ²⁴, Judith James ²⁵, Andreas Jönsen ²⁶, Kenneth C Kalunian ²⁷, Diane Kamen ²⁸, S Sam Lim ²⁹, Eric Morand ³⁰, Christine Peschken ³¹, Bernardo A. Pons-Estel ³², Anisur Rahman ³³, Rosalind Ramsey-Goldman ³⁴, Juanita Romero-Diaz ³⁵, Guillermo Ruiz-Irastorza ³⁶, Jorge Sanchez-Guerrero ³⁷, Kristjan Steinsson ³⁸, Elisabet Svenungsson ³⁹, Murray Urowitz ⁴⁰, Ronald van Vollenhoven ⁴¹, Evelyne Vinet ⁴², Alexandre Voskuyl ⁴³, Daniel J Wallace ⁴⁴ and Graciela Alarcón ⁴⁵, ¹National University of Singapore, Singapore, Singapore, ²Changi General Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Allegheny Health Network, Pittsburg, PA, ⁶University of Calgary, Calgary, AB, Canada, ⁷Feinstein Institute for Medical Research, Manhasset, NY, ⁸Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁹Columbia University Medical Center, New York, NY, ¹⁰Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹²University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹³NYU School of Medicine, New York, ¹⁴University of Alabama Medical Center, Birmingham, AL, ¹⁵Cochin University Hospital, Paris, France, ¹⁶UnC Kidney Centre, Chapel Hill, NC, ¹⁷Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁸State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁹Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁰University of Birmingham, Birmingham, United Kingdom, ²¹Dalhousie University, Halifax, NS, Canada, ²²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²³Centre for Rheumatology, London, United Kingdom, ²⁴Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ²⁵Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁶Lund University, Lund, Sweden, ²⁷UC San Diego School of Medicine, LaJolla, CA, ²⁸Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²⁹Emory University, Atlanta, GA, ³⁰Monash University, Melbourne, Victoria, Australia, ³¹University of Manitoba, Winnipeg, Canada, ³²Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño, Rosario, Rosario, Argentina, ³³University College London, London, United Kingdom, ³⁴Northwestern University, Chicago, IL, ³⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ³⁶Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ³⁷Toronto Western Hospital, Toronto, ON, Canada, ³⁸Landspitali, University Hospital, Reykjavik, Iceland, ³⁹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴⁰University Health Network, University of Toronto, Toronto, ON, Canada, ⁴¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴²McGill University Health Centre, Montreal, QC, Canada, ⁴³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴⁴Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁴⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The impact of glucocorticoid (GC) use on major organ damage in SLE patients has not been formally studied by amalgamating the relevant data published…
Abstract Number: 2811 • 2019 ACR/ARP Annual Meeting
The IRE1α Pathway Mediates Neutrophil Stress and NETosis in Lupus
Gautam Sule¹, Basel Abuaita ¹, Paul Steffes ¹, Kristen Gilley ¹, Andrew Fernandes ¹, Mary O’Riordan ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Immune complex (IC)-activated neutrophils appear to amplify inflammation in lupus through the release of neutrophil extracellular traps (NETosis). There is presently no consensus as…
Abstract Number: 2045 • 2019 ACR/ARP Annual Meeting
RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets
Taylor Koenig¹, Nicholas Young ², Giancarlo Valiente ³, Ifeoma Okafor ⁴, Emily Schwarz ⁵, Peter Harb ⁵, Caitlin Henry ¹, Kyle Jablonski ⁶, Lai-Chu Wu ⁴, Eli Roberson ⁷ and Wael Jarjour ⁸, ¹Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ³The Ohio State University, Columbus, ⁴Ohio State College of Medicine, Columbus, ⁵The Ohio State University Wexner Medical Center, Columbus, OH, ⁶The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ⁷Washington University at St.Louis, St.Louis, MO, ⁸Ohio State College of Medicine, Columbus, OH
Background/Purpose: Systemic lupus erythematosus is an autoimmune disease characterized by chronic inflammation. We have previously shown that TLR7 and TLR8 are significantly upregulated in PBMCs…
Abstract Number: 77 • 2019 ACR/ARP Annual Meeting
Flux Analysis Reveals Influence of Rab4 Expression on Mitochondrial and Pentose Phosphate Pathway Metabolism of Lupus T Cells
Tamas Faludi¹, Nick Huang ¹, Manuel Duarte ², Joshua Lewis ² and Andras Perl ³, ¹Upstate Medical University, Syracuse, NY, ²Upstate Medical University, Syracuse, ³SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: HRES-1/Rab4 is a small GTPase enzyme which regulates endosomal trafficking. The protein is overexpressed in T cells of SLE patients (J Immunol. February 15,…
Abstract Number: 650 • 2019 ACR/ARP Annual Meeting
Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients
Eunyoung Lee¹, Eun Bong Lee ², Eun Young Lee ¹, Jin Kyun Park ³, Se Han Ahn ⁴ and Yeong-Wook Song ⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Gwacheon-si, Kyonggi-do, Republic of Korea, ⁵Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: To evaluate the performance of the proposed American College of Rheumatology/European League against Rheumatism (ACR/EULAR) classification criteria for systemic lupus erythematosus (SLE) in Korean…
Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Shanthini Kasturi¹, John Wong ¹, Lisa Mandl ², Timothy McAlindon ³ and Amy LeClair ¹, ¹Tufts Medical Center, Boston, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ³Tufts Medical Center, Boston, MA
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…
Abstract Number: 1029 • 2019 ACR/ARP Annual Meeting
Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis
Neelakshi R. Jog¹, Wade DeJager ¹, Joel Guthridge ² and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…
Abstract Number: 1188 • 2019 ACR/ARP Annual Meeting
Novel PET-Coronary Flow Reserve Imaging to Assess for Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Compared to Subjects with Diabetes Mellitus and Controls
Cameron Speyer¹, Corine Sinnette ¹, Emma Stevens ¹, Hongshu Guan ², Courtney Bibbo ², Marcelo Di Carli ², Karen Costenbader ¹ and Elena Massarotti ², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: High risk of premature cardiovascular disease (CVD) among SLE patients is well documented, but the best means to detect the earliest stages of CVD…
Abstract Number: 1586 • 2019 ACR/ARP Annual Meeting
All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database
Rashmi Dhital¹, Dilli Ram Poudel ², Ramesh Kumar Pandey ³ and Paras Karmacharya ⁴, ¹Reading Hospital ,PA, Shillington, PA, ²University of Pennsylvania, Philadelphia, ³Fox Chase Hospital, Philadelphia, ⁴Reading Hospital, Mayo Clinic, Rochester
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disorder with variable presentation. While several studies have outlined the risk factors for hospitalization and…
Abstract Number: 1624 • 2019 ACR/ARP Annual Meeting
Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients
Maria del Carmen Zamora Medina¹, Jessica Roldan Ortega ², Mario Cesar Ocampo Torres ³, Pilar Lara Reyes ¹, Alba Cicero Casarrubias ¹, Ivon Bautista Mejia ¹ and Juanita Romero-Diaz ⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, Mexico, ²Monterrey Institute of Technology and Higher Education, MEXICO CITY, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico
Background/Purpose: The aims of our study were to determine the cumulative prevalence of damage at baseline, 5 years and 10 years of follow-up, to identify…
Abstract Number: 1914 • 2019 ACR/ARP Annual Meeting
Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Cristina Arriens¹, Quratul Raja ², Syed Ali Husain ², Bessy George ², Majid Abedi ³, Aviva Jacobs ⁴, Timothy Guyon ⁴, Hemani Wijesuriya ³, Teresa Aberle ⁵, Aikaterini Thanou ⁵, Stan Kamp ⁵, Susan R. Macwana ⁵, Eliza F. Chakravarty ¹, Joan T. Merrill ⁶, Judith James ¹, Robert Terbrueggen ⁴ and Joel Guthridge ¹, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³DxTerity Diagnostics Inc, Anaheim, CA, ⁴DxTerity Diagnostics Inc, Rancho Dominguez, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The interferon (IFN) signature in SLE is well established, distinguishing lupus patients from healthy controls. Additionally, within lupus patients, higher levels of IFN-responsive gene…
Abstract Number: 2127 • 2019 ACR/ARP Annual Meeting
Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics
Judit Morello ¹, Sara M. Teixeira ¹, João Rodrigues ², Sara Maia ³, Atlas Sardoo ⁴, Rita Pinheiro Torres ⁵, Sofia A. Pereira ⁴, Jaime Branco ⁶, Alexandra Antunes ⁷ and Fernando Pimentel-Santos⁴, ¹Centro de Química Estrutural, Instituto Superior Técnico, Ulisboa, Lisboa, Portugal, ²Clarify Analytical, Évora, Portugal, ³CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ⁴Centro de Estudos de Doenças Crónicas (CEDOC), Nova Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal, lisboa, Portugal, ⁵Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ⁶CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ⁷Centro de Química Estrutural, Instituto Superior Técnico, Ulisboa,, Lisboa, Portugal
Background/Purpose: Early diagnosis of inflammatory rheumatic diseases (IRD), as axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) represents in our days a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].